Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of CellRight in 2017, TRX revised its commercial strategy, to service the strong demand for its products. However, this necessitated capacity expansion and realignment of its supply chain, which affected 2019 trading and forced renegotiation of its MidCap loan arrangement. In our view, the current share price reflects TRX’s need for a capital injection.
06 Feb 2020
Restructured to satisfy product demand
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Restructured to satisfy product demand
Tissue Regenix Group plc (TRX:LON) | 61.5 0 0.0% | Mkt Cap: 43.4m
- Published:
06 Feb 2020 -
Author:
Martin Hall -
Pages:
12
Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. It has two proprietary decellularisation technology platforms for repair of soft tissue (dCELL) and bone (BioRinse). Following the acquisition of CellRight in 2017, TRX revised its commercial strategy, to service the strong demand for its products. However, this necessitated capacity expansion and realignment of its supply chain, which affected 2019 trading and forced renegotiation of its MidCap loan arrangement. In our view, the current share price reflects TRX’s need for a capital injection.